Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in adults with reduced ejection ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The firm has a market cap of $228.84 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 1.42 and a beta ...

For this article, we used a Finviz screener to filter all the available ADR stocks. Then we compare the list with our Q4 2024 ...

AstraZeneca PLC (NASDAQ ... has a strong pipeline and product portfolio featuring drugs such as Tagrisso, Farxiga, and Symbicort. AZN also engages in strategic collaborations with biotech firms ...